Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age

BACKGROUND: A dose-sparing inactivated polio vaccine (IPV-Al), obtained by adsorption of inactivated virus to an aluminium hydroxide adjuvant, can help mitigate global supply and the cost constraints of IPV. The objective of this trial was to demonstrate the non-inferiority of IPV-Al to standard IPV...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Vaccine
Autores principales: Bravo, Lulu C., Carlos, Josefina C., Gatchalian, Salvacion R., Montellano, May Emmeline B., Tabora, Charissa Fay Corazon B., Thierry-Carstensen, Birgit, Tingskov, Pernille Nyholm, Sørensen, Charlotte, Wachmann, Henrik, Bandyopadhyay, Ananda S., Nielsen, Pernille Ingemann, Kusk, Mie Vestergaard
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier Science 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6983932/
https://ncbi.nlm.nih.gov/pubmed/31703934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2019.10.064
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares